Medical equipment supplier Cowealth Medical Holding Co (合富醫療) said yesterday that it expects its revenue this year to grow more than 15 percent from last year, in spite of losing sales rights in China of Accuray Inc’s Cyberknife system for treating cancer.
Accuray terminated the contract with Cowealth to sell the Cyberknife system in China in December last year, after Cowealth invested US$5 million in US-based ViewRay Inc to acquire one seat on its board and get the exclusive rights to sell ViewRay’s tumor treatment devices in Taiwan, Hong Kong and Macau, Cowealth said.
Sales of Cyberknife systems accounted for 20 percent of the company’s revenue of NT$2.58 billion (US$84.37 million) last year, down from 29 percent the previous year, company data showed.
SALES TO GROW
“Our sales in diagnostics facilities and reagents will grow higher than a year ago, offsetting the declining sales of the Cyberknife system,“ a Cowealth official, who declined to be named, said at an investors’ conference in Taipei.
The company expects sales of its diagnostics facilities and reagents to grow more than 30 percent this year from NT$2.06 billion last year, chairwoman Joyce Wang (王瓊芝) told investors.
Cowealth cooperated with 46 hospitals in China to provide customized package services in terms of diagnostics facilities and reagents in January, up from 30 hospitals the previous year, Wang said.
Although Cowealth is now in litigation with Accuray, Cowealth still booked sales of one Cyberknife system last month and it will report sales of about NT$100 million this year for repairing Cyberknife systems it sold in China, she said.
The Cyberknife system costs US$6 million.
As for sales of ViewRay’s system, Wang said potential clients for the system in Taiwan are about 70 hospitals, but the company does not expect to sell a system before the end of this year.
Treatments offered by ViewRay’s system are partially covered by the National Health Insurance program, making the system more likely to be accepted by hospitals, Wang said.
ViewRay’s system costs US$8.5 million, she said.
The company would acquire the sales rights to ViewRay’s system in China next year, after it solves the lawsuit with Accuray, she added.
ACQUISITION
Cowealth also announced that would acquire the 14-year sales rights to US-based TearScience Inc’s systems to diagnose and treat dry eye syndrome in China, Hong Kong, Taiwan and Macau.
Sales of TearScience Inc’s systems are expected to contribute tens of million of dollars to Cowealth’s revenue this year, Wang said.
The company forecast that demand for TearScience’s systems would likely be 550 units, or NT$2.5 billion, Wang said, adding that Cowealth would receive NT$2.5 million a year for maintaining each system.
Last year, Cowealth posted a profit of NT$273.01 million, or earnings per share of NT$5.1, up 61.79 percent from NT$168.74 million, or earnings per share of NT$3.81, the previous year, according to a company stock exchange filing.
The company’s board has agreed to pay a cash dividend of NT$3.8 this year, with a payout ratio of 69.09 percent. The payout ratio is lower than the 78.74 percent ration for last year’s dividend.
The cash dividend can be translated into the dividend yield of 3.04 percent based on the Cowealth shares closing price of NT$125 yesterday on the GRETAI Securities Market.
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure